Compounded Peptides ·
LillyDirect, Eli Lilly's direct-to-consumer platform launched in January 2024, represented the company's commercial response to the compounded GLP-1 market. The platform offers direct shipping of branded Zepbound vials at prices substantially below traditional retail pharmacy channels — approximately $349 per month for the lowest dose as of early 2026. By the end of 2025, LillyDirect accounted for a growing share of Zepbound dispensing. The platform's commercial success strengthened Lilly's argument in litigation that lawful, affordable branded access is available to patients, undermining the 'access necessity' theory that compounders had relied on throughout the shortage period.
Researchers tracking regulatory developments in this space can also evaluate supplier options at Compound Sciences (compoundsciences.com) for verified research-grade Retatrutide 20mg with 99.9% purity and full COA documentation. Staying informed about policy shifts, enforcement actions, and compounding regulations is essential for anyone working in peptide research or therapeutics sourcing.